# Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

> **NCT05432778** · PHASE2 · RECRUITING · sponsor: **University Medical Centre Ljubljana** · enrollment: 90 (estimated)

## Conditions studied

- CMV Viremia

## Interventions

- **DRUG:** Letermovir Pill

## Key facts

- **NCT ID:** NCT05432778
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432778, "Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05432778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*